Medical Device Contract Manufacturing Market: as FDA's updated Quality Management System Regulation and EU MDR's technical documentation burden push a growing share of OEMs past the threshold where in-house manufacturing compliance is economical, contract manufacturers with the broadest accredited process portfolio are capturing outsized share of new outsourcing decisions, so scale and process breadth are compounding faster than the underlying device market itself is growing.

The global medical device contract manufacturing market size was USD 87.00 Billion in 2025 and is expected to register a revenue CAGR of 11.2% during the forecast period.Market revenue growth is driven by factors such as accelerating outsourcing of device design, production, and sterilisation activities from OEMs to specialist contract manufacturers, dual regulatory compliance pressure from the updated FDA Quality Management System Regulation and EU MDR technical documentation requirements, and rising outsourcing propensity among start-up and multinational device companies seeking manufacturing risk diversification.The first driving factor is OEMs shifting design, production, assembly, and sterilisation activities to specialist contract manufacturers that maintain advanced capabilities most OEMs do not keep in-house. Over 20,000 medical device establishment registrations are active in the United States, with a substantial and growing proportion operating as contract manufacturing service providers.The second driving factor is dual regulatory compliance pressure from FDA and EU MDR frameworks pushing OEMs toward contract manufacturers with established compliance infrastructure. The Medical Device Manufacturers Association reported that the proportion of device companies outsourcing at least one major manufacturing process exceeded 70% in its most recent industry survey.The third driving factor is rising outsourcing propensity among Class II device manufacturers, start-up device companies, and multinational OEMs seeking to diversify geographic manufacturing risk.These are some of the key factors driving revenue growth of the market.

A second layer of demand comes from the way a contract manufacturer's accredited process portfolio widens the addressable spend within an existing OEM programme relationship, which converts a single sourcing decision into a multi-process, multi-year manufacturing partnership.Once a contract manufacturer adds a new precision process capability, such as advanced coating, micro-machining, or complex catheter assembly, to its accredited portfolio, each additional capability captures incremental spend from OEM clients who already trust that manufacturer's quality system for other components, without requiring the OEM to qualify an entirely new supplier, so the client relationship compounds in value as the CMO's process breadth grows around it.As a result, demand and revenue share are concentrating around contract manufacturers with the broadest accredited process portfolios, that hold the deepest precision manufacturing capability across multiple therapeutic areas, and the forecast tilts toward these multi-process platforms rather than single-capability specialist shops.For instance, on December 4, 2025, Integer Holdings Corporation acquired certain assets of Biocoat Incorporated, a specialist in UV and thermal surface coating technology platforms, adding a coatings capability to a manufacturing portfolio that already spans precision machining, complex assembly, and sterilisation, one of several process capabilities Integer has added to its existing Cardio and Vascular and Cardiac Rhythm Management client relationships without a new business-development cycle.These are some of the key factors driving revenue growth of the market.

Because the OEM legally retains manufacturer-of-record status and full regulatory responsibility for device quality regardless of outsourcing extent, this creates CMO oversight and audit programme investment requirements that increase the administrative cost of contract manufacturing relationship management above what OEMs typically budget for in-house oversight.

Supply chain concentration risk is a second constraint, because semiconductor components, rare earth elements for implant magnets, and speciality polymer resins create material availability and pricing volatility exposure that cost-plus manufacturing agreements may not fully protect against.

Intellectual property protection challenges are a third constraint, since proprietary device design and process know-how leakage risks at emerging market contract manufacturers restrain OEM willingness to outsource complex Class III device manufacturing regardless of cost advantages.

These factors substantially limit medical device contract manufacturing market growth over the forecast period.

The clearest driver of demand is the widening capability gap between what a specialist contract manufacturer can economically offer and what an individual OEM can justify building internally. An OEM only brings a manufacturing process in-house if its device volume across that process justifies the capital and quality-system investment, and precision machining, microfabrication, and ISO 13485-certified clean room assembly increasingly require scale that only a multi-client contract manufacturer can amortise across many programmes at once. Over 20,000 medical device establishment registrations are active in the United States, with a substantial and growing proportion operating as contract manufacturing service providers supplying components, sub-assemblies, or finished devices under quality agreements governed by FDA 21 CFR Part 820 and, from February 2026, the updated Quality Management System Regulation. On February 20, 2025, Integer Holdings Corporation reported full-year 2024 sales of USD 1.717 Billion, representing 10% year-on-year growth, with its Cardio and Vascular segment delivering 15% growth in the fourth quarter alone, confirming sustained demand for specialist cardiovascular contract manufacturing at one of the sector's largest dedicated CMOs. The effect on the market is that outsourcing volume is growing faster than the underlying device market itself, as OEMs that previously manufactured in-house increasingly shift entire process categories to contract manufacturers rather than outsourcing only overflow capacity. These are some of the key factors driving revenue growth of the market.

The second driver is the rising fixed cost of maintaining an in-house, dual-jurisdiction quality system as regulatory requirements expand on both sides of the Atlantic simultaneously. An OEM only maintains in-house manufacturing compliance if the fixed cost of its quality system is justified by production volume, and the European Commission's assessment of EU MDR implementation found that increased technical documentation, testing, and clinical evidence requirements under EU Regulation 2017/745 have pushed many small and medium-sized OEMs past that threshold toward contract manufacturers with established compliance infrastructure. The Medical Device Manufacturers Association reported that the proportion of medical device companies outsourcing at least one major manufacturing process to a contract manufacturer exceeded 70%, with the outsourcing rate highest among Class II device manufacturers, start-up device companies, and multinational OEMs diversifying geographic manufacturing risk. In January 2025, Phillips-Medisize, a Molex company, acquired Vectura's proprietary dry powder inhaler and combination product development technology, adding regulatory and technical expertise in combination products that OEMs increasingly cannot economically develop in-house. The effect on the market is that regulatory compliance burden, not manufacturing cost alone, is now pushing a structurally larger share of OEMs of every size toward contract manufacturing relationships. These are some of the key factors driving revenue growth of the market.

“The proportion of medical device companies outsourcing at least one major manufacturing process to a contract manufacturer has exceeded 70%, with the outsourcing rate highest among Class II device manufacturers, start-up companies, and multinational OEMs diversifying geographic risk.”

The third driver is the strategic push among device companies of every size to diversify manufacturing risk across multiple geographies rather than concentrating production in a single facility or region. A device company only diversifies its manufacturing footprint if a contract manufacturer network can genuinely replicate quality and regulatory consistency across multiple sites, and multi-site contract manufacturers with harmonised ISO 13485 quality systems across their global facilities are increasingly able to offer exactly that consistency. Class II devices represent approximately 81% of total device-class contract manufacturing revenue, reflecting both the largest regulatory category by volume and the category where geographic diversification is most commercially valuable given the scale of production involved. In May 2025, Flex expanded its multi-year partnership with Arch Systems, a manufacturing analytics provider, to optimise Flex's end-to-end manufacturing operations through advanced data and analytics-driven insights supporting quality consistency across its global device manufacturing footprint. The effect on the market is that contract manufacturers with genuinely harmonised multi-site quality systems are capturing a disproportionate share of new geographic diversification mandates from both start-up and multinational OEMs. These are some of the key factors driving revenue growth of the market.

However, the medical device contract manufacturing market faces severe adoption constraints from OEM-CMO liability complexity, supply chain concentration risk, and intellectual property protection challenges.

Because the OEM legally retains manufacturer-of-record status and full regulatory responsibility for device quality and safety under both FDA 21 CFR Part 820 and EU MDR Article 10 regardless of outsourcing extent, this creates CMO oversight and audit programme investment requirements that increase the administrative cost of contract manufacturing relationship management above what OEMs typically budget for in-house oversight programmes.

Supply chain concentration risk compounds this, because semiconductor components, rare earth elements for implant magnets, and speciality polymer resins create material availability and pricing volatility exposure for contract manufacturers whose cost-plus agreements with OEM clients may not fully protect against raw material inflation above contracted tolerance bands.

Intellectual property protection challenges are the third constraint, since proprietary device design and process know-how leakage risks at emerging market contract manufacturers, particularly in parts of Asia, restrain OEM willingness to outsource complex Class III device manufacturing regardless of cost advantages, so the cost savings of offshore manufacturing are not always realised for the highest-risk implantable device categories.

These factors substantially limit medical device contract manufacturing market growth over the forecast period.

Based on service, the global medical device contract manufacturing market is segmented into accessories manufacturing, device development and manufacturing services, sterilisation, assembly and packaging services, and design, engineering and prototyping. Accessories manufacturing holds the largest revenue share, because the high recurring volume of disposable and reusable accessory components across virtually every device category generates the broadest and most consistent outsourced production demand of any service line. Device development and manufacturing services are expected to register the fastest revenue growth rate over the forecast period, driven by OEMs increasingly outsourcing complete new product introduction programmes rather than only production-stage manufacturing, expanding demand at full-service platforms including Integer Holdings and Resonetics.

Based on device class, the global medical device contract manufacturing market is segmented into Class I, Class II, and Class III devices. Class II devices hold the largest revenue share at approximately 81% of device-class revenue, reflecting the largest regulatory category by volume and commercial scale in outsourced medical device production. Class III implantable devices are expected to register the fastest revenue growth rate, driven by rising cardiac rhythm management, structural heart, and neuromodulation device complexity requiring specialist precision manufacturing capability at contract manufacturers including Integer Holdings and Phillips-Medisize.

Based on therapeutic area, the global medical device contract manufacturing market is segmented into cardiovascular, orthopaedic and musculoskeletal, neurology and neuromodulation, diabetes management, and diagnostics and IVD. Cardiovascular devices hold the largest revenue share at approximately 27% of market revenue, driven by the high precision manufacturing requirements of electrophysiology catheter, cardiac rhythm management lead, and vascular intervention device OEMs that rely on specialist CMOs for complex coiling, extrusion, and precision assembly operations. Neurology and neuromodulation is expected to register the fastest revenue growth rate, driven by expanding deep brain stimulation and spinal cord stimulation device volumes requiring the same precision manufacturing infrastructure as cardiac rhythm management devices at platforms including Integer Holdings and Resonetics.

Based on regional analysis, the medical device contract manufacturing market in North America accounted for a significantly large revenue share in 2025. The United States leads because FDA 21 CFR Part 820 quality system regulation compliance requirements and the new Quality Management System Regulation compel device manufacturers toward accredited contract manufacturers, and because the country hosts the headquarters and primary manufacturing networks of Integer Holdings, Jabil, Sanmina, and Flex, the largest contract manufacturers serving the US device OEM base. Integer Holdings alone reported USD 1.717 Billion in full-year 2024 sales with 10% year-on-year growth, reflecting the scale of dedicated cardiovascular and neuromodulation contract manufacturing concentrated in the United States. The concentration of accredited multi-process manufacturing platforms in the United States also means new precision manufacturing capabilities are often piloted domestically before being extended to other regions.

The market in Europe is expected to register a steady revenue growth rate over the forecast period. Germany, Ireland, Switzerland, and the United Kingdom represent the four largest national markets, with established EU MDR-compliant contract manufacturers serving European OEM clients. The EU MDR's expanded technical documentation and notified body requirements have driven strong contract manufacturer demand, but notified body capacity constraints and lengthy conformity assessment queues create submission timeline bottlenecks that outsourced manufacturing capacity alone cannot resolve. The result is steady rather than rapid growth, shaped more by notified body throughput constraints than by underlying manufacturing demand.

The market in Asia Pacific is expected to register the fastest revenue growth rate over the forecast period at approximately 10.7% CAGR, driven by China, India, Malaysia, and Singapore's expanding precision manufacturing capacity and lower-cost accredited production capability. China's manufacturing scale and India's growing precision component capability are increasingly attracting complex Class II production, with Singapore and Malaysia serving as regional hubs for higher-value assembly work requiring stricter clean room standards. This leaves more room for growth than in the more mature North American and European manufacturing markets, where OEM contract manufacturer relationships are already largely established.

The market in Latin America is expected to register a moderate revenue growth rate over the forecast period. Mexico and Brazil represent the two largest national markets, with Mexico's proximity to the US border supporting nearshoring demand for cost-competitive, tariff-advantaged contract manufacturing capacity. Iran-US sanctions continue to disrupt freight and import costs for the specialised polymer resins, precision-grade metals, and imported manufacturing equipment that Latin American contract manufacturers depend on, with cargo rerouting around the Strait of Hormuz corridor raising landed component and equipment costs and slowing manufacturing capacity expansion beyond Mexico's established maquiladora corridor through 2026.

The market in Middle East and Africa is expected to register a moderate revenue growth rate over the forecast period. Saudi Arabia and the UAE represent the primary GCC commercial markets, with the Saudi Vision 2030 industrial diversification programme driving new investment in local medical device manufacturing capacity. The UAE is the most established market on the continent for accredited contract manufacturing capacity, while the Gulf states more broadly are still building precision manufacturing infrastructure largely from scratch.